Clinically isolated syndrome and radiologically isolated syndrome

01OverviewDefinition, clinical context and the essential points that orientate the chapter.

Clinically isolated syndrome begins with a person and a lesion that agree. A painful monocular optic neuropathy, partial spinal-cord syndrome or discrete brainstem deficit evolves over hours to days, lasts beyond 24 hours and has objective findings. MRI may reveal only the symptomatic lesion or additional silent lesions. Under modern diagnostic criteria, silent lesions, contrast enhancement and cerebrospinal-fluid oligoclonal bands can establish multiple sclerosis at the first episode in defined circumstances. The clinician must first show that the event is typical and that a more plausible diagnosis does not explain it.

Radiologically isolated syndrome begins with an image, usually obtained for trauma, headache or another unrelated reason. Lesions have morphology and distribution characteristic of central demyelination, yet careful history and examination uncover no attributable clinical attack or ongoing deficit. Under the 2024 revised McDonald criteria, selected radiologically isolated presentations can fulfil diagnostic criteria for multiple sclerosis; the label must therefore be applied by a specialist, not by automated report wording or a lesion-count shortcut. Vascular risk, migraine, toxic exposure, infection, systemic inflammation and inherited disorders remain important mimics, and spinal imaging or cerebrospinal fluid can refine classification and risk.

Counselling should avoid both false reassurance and inevitability. Some people never have a clinical event, while spinal lesions, younger age, enhancement, lesion accrual and intrathecal immune markers increase risk. A person may satisfy current diagnostic criteria before a clinical attack, but diagnosis and treatment eligibility are separate decisions. Follow-up MRI and any disease-modifying therapy discussion require specialist interpretation of current criteria, trial evidence, licensing and NHS commissioning; new symptoms must still be investigated on their own merits.

Key points

Clinically isolated syndrome is a first objective neurological episode caused by central inflammatory demyelination, lasting at least 24 hours, in a person not yet shown to meet full multiple-sclerosis criteria.
Typical clinically isolated syndromes are unilateral optic neuritis, partial transverse myelitis, a brainstem event or a cerebellar syndrome; vague dizziness, fatigue or paraesthesia without objective localisation is less specific.
Some first events already meet contemporary multiple-sclerosis criteria through MRI dissemination and cerebrospinal-fluid biomarkers, so clinically isolated syndrome is not a mandatory prolonged waiting stage.
Radiologically isolated syndrome describes MRI lesions highly characteristic of demyelination discovered in someone without historical or current clinical manifestations attributable to them.
Migraine, age-related small-vessel disease, vasculitis, previous infection and genetic white-matter disorders can mimic radiological isolation; lesion shape and location must be reviewed by experienced neuroradiology and neurology teams.
Future clinical-event risk after either syndrome rises with younger age, spinal-cord or infratentorial lesions, gadolinium enhancement, new lesions over time and cerebrospinal-fluid-specific oligoclonal bands.
Test serum aquaporin-4 and MOG antibodies when optic neuritis or myelitis is severe, bilateral, recurrent, longitudinally extensive or otherwise atypical for ordinary multiple sclerosis.
High-dose methylprednisolone may accelerate recovery from a functionally significant clinical attack but does not convert an incidental radiological syndrome into a symptomatic relapse.
Disease-modifying therapy can be appropriate after a high-risk clinical syndrome or when current multiple-sclerosis criteria are met; exact licensing and NHS eligibility require specialist confirmation.
Selected people with radiologically isolated syndrome can now fulfil the 2024 revised McDonald criteria for multiple sclerosis, but diagnosis does not itself mandate disease-modifying treatment; evidence, licensing, NHS eligibility, risks and patient preference still require specialist review.

02AetiologyUnderlying causes, associations and risk factors, with why each one matters.

Early MS-spectrum autoimmunity

A first focal demyelinating attack or characteristic silent lesions may represent the earliest detectable expression of multifactorial central nervous-system autoimmunity that later fulfils multiple-sclerosis criteria.

Antibody-associated alternatives

Aquaporin-four or MOG-associated inflammation can initially resemble a clinical demyelinating syndrome, particularly with severe bilateral optic neuritis or extensive myelitis.

Unexplained radiological isolation

Some people develop highly characteristic demyelinating-appearing lesions without recalled symptoms or an identified precipitant, and their future clinical course remains variable.

03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.

1
Focal immune infiltration
Immune cells cross the blood–brain barrier and create a local area of inflammation, demyelination and variable axonal injury within brain, optic nerve or spinal cord.
2
Clinical or silent conduction failure
A lesion produces an objective neurological syndrome when it disrupts an eloquent pathway; similar inflammation may remain asymptomatic when reserve and location permit compensation.
3
Dissemination or quiescence
New inflammatory lesions may appear in different locations and times, establishing multiple sclerosis, while other individuals remain clinically and radiologically stable.

04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.

Typical optic event

Subacute painful monocular visual loss with reduced colour vision, central field change and a relative afferent pupillary defect is a classic clinical demyelinating syndrome.

Partial cord event

Asymmetric sensory and motor symptoms, a definable level, Lhermitte phenomenon or sphincter change evolving over days can represent a focal inflammatory spinal lesion.

Brainstem syndrome

Internuclear ophthalmoplegia, a focal trigeminal sensory syndrome or persistent diplopia with an anatomically concordant lesion is more specific than isolated light-headedness.

Radiological discovery

Characteristic ovoid periventricular, callosal, cortical or infratentorial lesions are found incidentally, and detailed questioning confirms no previous neurological episode matching their location.

Atypical severe eventRed flag

Bilateral optic involvement, chiasmal disease, complete myelitis, longitudinally extensive cord signal or area-postrema symptoms suggest aquaporin-4 or MOG-associated disease and need urgent specialist assessment.

Higher conversion risk

Spinal or infratentorial lesions, gadolinium activity, new lesions on surveillance, younger age and cerebrospinal-fluid-restricted oligoclonal bands increase the likelihood of future clinical disease.

05InvestigationsWhat to request, why it matters and how to interpret it.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
MRI brain with demyelination protocolFirst step
Why
Assess lesion morphology, distribution, enhancement and evidence of dissemination.
Interpretation and limitations
Specialists distinguish ovoid perivenular and callosal lesions from punctate vascular or migraine changes; contrast timing and prior imaging determine evidence of new activity.
02
MRI cervical and thoracic spinal cord
Why
Confirm a symptomatic cord lesion, exclude compression and refine risk after an incidental brain scan.
Interpretation and limitations
Short peripheral lesions fit multiple sclerosis more readily; long central lesions, swelling or vascular patterns require broader antibody, inflammatory and vascular evaluation.
03
Lumbar puncture with paired oligoclonal bands
Why
Support intrathecal inflammation and refine diagnosis or future-event risk.
Interpretation and limitations
Cerebrospinal-fluid-specific bands can contribute to multiple-sclerosis criteria in an eligible clinical syndrome, but are not unique to it and must be paired with serum.
04
AQP4-IgG and MOG-IgG
Why
Identify alternative relapsing inflammatory disorders when attack phenotype is atypical.
Interpretation and limitations
Serum cell-based testing has the greatest value when requested for a compatible syndrome; specialist interpretation prevents overcalling low-probability or low-titre results.
05
Visual assessment, OCT and evoked potentials
Why
Objectify optic-nerve involvement or seek selected silent pathway dysfunction.
Interpretation and limitations
Afferent pupillary defect, dyschromatopsia, retinal-layer change and delayed visual conduction support optic neuropathy, while retinal disease and glaucoma must be excluded.
06
Targeted mimic screen
Why
Exclude nutritional, vascular, infectious, systemic inflammatory and genetic explanations.
Interpretation and limitations
Blood pressure and vascular risk, B12, folate, thyroid and selected HIV, syphilis, copper or autoimmune tests follow age, imaging and phenotype rather than a fixed blanket panel.
07
Surveillance MRI
Why
Detect new silent lesions that materially change risk or diagnostic criteria.
Interpretation and limitations
Use a comparable protocol and specialist-defined interval; minor sequence differences should not be mistaken for biological lesion accrual.

06Differential diagnosisRealistic alternatives and the features that help distinguish them.

Migraine and small-vessel change

Small non-specific white-matter lesions lacking characteristic shape and location favour migraine or vascular disease rather than true radiological isolation.

MOG-associated disease or NMOSD

Bilateral severe optic neuritis, longitudinally extensive myelitis or area-postrema symptoms should prompt antibody testing because prognosis and treatment differ from MS.

Vascular or compressive lesion

Abrupt maximal deficit or a structural cord abnormality favours infarction or compression; clinical tempo and directed imaging prevent mislabelling these as inflammatory demyelination.

Infection or systemic inflammation

Fever, meningism, marked cerebrospinal-fluid pleocytosis or systemic immune features require investigation for infectious, vasculitic and granulomatous mimics.

07ManagementImmediate care, first-line treatment, alternatives and escalation.

01First clinical eventVerify objective demyelinationFirst stepA first optic, cord, brainstem or cerebellar syndrome evolves over hours to days.

1Localise with a full neurological and ophthalmic examination, documenting duration, functional impact, previous subtle attacks and vascular, compressive, infectious or systemic clues.
2Arrange urgent imaging for severe cord or brainstem disease and specialist protocol brain and spinal MRI for a stable typical event, adding cerebrospinal fluid when it changes criteria.
3Apply current diagnostic criteria through neurology, communicating whether the outcome is multiple sclerosis, clinically isolated syndrome or unresolved atypical inflammation.

02Incidental lesionsConfirm radiological isolation before labellingAn MRI performed for another reason reports lesions possibly consistent with demyelination.

1Review original images with neuroradiology rather than relying on report wording, comparing morphology and distribution with migraine and small-vessel-disease patterns.
2Take a directed lifetime neurological history and perform examination to ensure there has been no attributable clinical event, then assess vascular and systemic mimics.
3Refer to neurology for spinal MRI, cerebrospinal fluid and surveillance decisions; provide balanced counselling without stating that future multiple sclerosis is inevitable.

03Acute recoveryTreat disability, not the scanA clinically isolated attack causes meaningful visual, motor, sensory or balance impairment.

1AlternativeExclude infection and alternative emergency causes, then discuss high-dose methylprednisolone when faster recovery would provide important functional benefit.
2Add physiotherapy, occupational, visual and bladder support according to the deficit, explaining that corticosteroid response cannot confirm the eventual diagnosis.
3Review recovery and MRI or cerebrospinal-fluid risk promptly so eligibility for disease-modifying treatment is considered rather than waiting for preventable additional injury.

04Surveillance choiceManage future-event risk explicitlyClinically or radiologically isolated disease remains after the diagnostic assessment.

1Stratify spinal and infratentorial burden, enhancement, new lesions, oligoclonal bands, age, pregnancy plans, comorbidity and the person's tolerance of uncertainty.
2For clinically isolated syndrome, discuss disease-modifying therapy when current diagnosis, licence and NHS criteria support it; for radiological isolation, explain the emerging but not universal treatment evidence.
3Agree clinical contact triggers and a standardised MRI interval, revisiting the diagnosis immediately after any objective neurological event or new radiological activity.

Key medicines and prescribing safety3 treatments · regimens, roles and cautions

Speeds recovery from a functionally important acute inflammatory episode while diagnostic assessment continues.

Methylprednisolone for a clinical attack

When a first demyelinating event is disabling, specialists may use the NICE multiple-sclerosis relapse regimen of 0.5 g orally daily for 5 days or selected intravenous therapy.

Exclude infection, review glucose and psychiatric risk, and explain that response neither proves multiple sclerosis nor prevents future conversion; incidental MRI lesions alone are not a steroid indication.

Can reduce further inflammatory events in eligible high-risk clinically isolated syndrome or newly diagnosed multiple sclerosis.

Disease-modifying therapy after CIS

Use only an agent and schedule licensed, NICE-approved and NHS-commissioned for the person's confirmed diagnosis and risk profile under an MS specialist.

Balance infection, malignancy, pregnancy, vaccine, monitoring and rebound risks; the applicable criteria and product licences change, so generic initiation is unsafe.

Selected high-risk radiologically isolated cases may discuss therapy intended to delay a first clinical event.

Disease-modifying therapy for RIS

There is no universal UK regimen; any treatment follows specialist interpretation of evolving diagnostic criteria, trial evidence, licensing and individual risk.

Avoid medicalising non-specific lesions or implying certain progression; long-term safety, overtreatment and commissioning uncertainties require explicit shared decision-making.

08ComplicationsImportant consequences, why they occur and why they matter clinically.

Future multiple sclerosis

Further clinical attacks or new characteristic lesions can establish multiple sclerosis and create accumulating motor, visual, sensory or cognitive disability.

Residual attack disability

Optic neuritis, myelitis or brainstem inflammation may leave impaired vision, gait, bladder function, pain or fatigue after the first event.

Diagnostic anxiety and overmedicalisation

An incidental scan label can create substantial uncertainty, repeated testing and altered life decisions despite the possibility that symptoms do not develop.

Treatment and surveillance burden

Disease-modifying treatment may reduce inflammatory risk in selected people but adds infection, reproductive and monitoring harms, while repeated imaging also carries practical and psychological cost.

09Monitoring and follow-upTreatment response, safety checks and longer-term review.

Document recovery from a clinical syndrome using visual acuity and colour, power, gait, sensation, bladder function and participation rather than symptoms alone.
Use the same MRI protocol and preferably comparable scanner for surveillance, recording genuinely new, enlarging or enhancing lesions through specialist review.
Ask at follow-up about discrete neurological episodes lasting beyond 24 hours, avoiding reinterpretation of momentary tingling or fatigue as definite attacks.
Reassess vascular risk, migraine and other mimic explanations when lesion evolution remains absent or the imaging pattern becomes less convincing.
If disease-modifying treatment starts, use its full blood, organ, infection, vaccination, pregnancy and MRI monitoring pathway with named ownership.
Support anxiety and uncertainty, providing a contact route and proportionate follow-up so surveillance neither disappears nor dominates the person's life.

10Special situationsVariants, exceptions and circumstances that change the usual approach.

CIS can be brief diagnostically

A first attack may already fulfil current multiple-sclerosis criteria through silent lesions and intrathecal evidence, removing the need to wait for a second clinical injury.

RIS requires no prior event

Once careful history or examination identifies a symptom attributable to a lesion, the case is no longer purely radiologically isolated.

Cord lesions increase risk

An asymptomatic spinal lesion is both more specific for demyelination than many tiny brain spots and associated with greater future clinical-event probability.

Criteria evolve

New biomarkers and anatomical regions may enter international criteria, but adoption, laboratory validation and NHS treatment eligibility remain specialist governance questions.

Treatment evidence differs

Benefits established for relapsing multiple sclerosis cannot simply be transferred to every incidental MRI, where absolute risk and overtreatment matter.

11Common pitfallsFrequent interpretation and management errors.

01
Calling vague sensory symptoms a clinically isolated syndrome without objective localisation.
02
Diagnosing radiologically isolated syndrome from a radiology report without reviewing images.
03
Ignoring migraine and vascular white-matter mimics in an incidental scan.
04
Missing compression or antibody-mediated disease in severe myelitis.
05
Giving corticosteroids for asymptomatic MRI enhancement alone.
06
Telling a person with radiological isolation that multiple sclerosis is inevitable.
07
Delaying specialist treatment discussion until a second disabling attack automatically occurs.